Peter R. Carroll, MD, MPH

Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer; Taube Family Distinguished Professorship in Urology, UCSF

Associate Director, Strategic Planning and Clinical Services; and Program Leader, Prostate Cancer Program, Helen Diller Family Comprehensive Cancer Center; Associate Dean, School of Medicine; Chair, Department of Urology, UCSF

Cancer Center Program Membership

Prostate Cancer

Research Summary

My main research interests include identifying clinical and pathologic determinants of prostate cancer recurrence, progression, and mortality; discovering novel biomarkers for prostate cancer diagnostics and prognostics; developing evidence-based guidelines for improved management of prostate cancer patients; and examining the impact of lifestyle on health-related quality of life and survivorship among men with prostate cancer. Since 1995, I have been PI of CaPSURE™, a national disease registry study of over 14,000 men with prostate cancer treated at 40+ sites. At UCSF, we have developed a novel program in clinical management of and research on active surveillance for men with low-burden prostate cancer. We are committed to reducing the burden of prostate cancer treatment (physical, psychological and monetary). In 2007, I and colleagues initiated the Prostate Cancer Active Surveillance Study (PASS), a large multi-institutional cohort of men on active surveillance, designed to examine quantitative metabolic, molecular, and physiologic imaging biomarkers and lifestyle factors as novel predictors of prostate cancer progression. We aim to better determine which patients may safely avoid radical treatment, while concurrently identifying men who may benefit from early treatment instead of active surveillance.

Research Funding

  • September 30, 2008 - July 31, 2018 - UCSF KURe Career Development Program, Co-Principal Investigator. Sponsor: NIH/NIDDK, Sponsor Award ID: K12DK083021
  • August 5, 1999 - September 29, 2012 - Cancer Center Support Grant, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: P30CA082103
  • September 30, 2009 - August 31, 2012 - Effectiveness of Early Stage Prostate Cancer Treatment, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: RC1CA146596
  • September 30, 2006 - September 29, 2011 - Male Reproductive Health Research Career Development Program, Principal Investigator. Sponsor: NIH/NICHD, Sponsor Award ID: K12HD053943

Education

University of California, Berkeley, BA, 1974, Zoology
Georgetown University School of Medicine, Washington, D.C., MD, 1979, Medicine
University of California, Berkeley, MPH, 2008

Honors & Awards

  • Other Experience and Professional Memberships
  • 2002-present
    American Urological Association, Prize Essay Committee (Chair)
  • 2002-2008
    American Urological Association, Update Series Advisory Committee (member)
  • 2001-present
    American Board of Urology, Trustee, President Elect (2006-2008)
  • 2001-present
    American College of Surgeons Commission on Cancer, AUA representative
  • 2000-present
    American Association of Genitourinary Surgeons, Site Committee
  • 2003-present
    American Association of Genitourinary Surgeons, Councilor
  • 2004-present
    ASCO Prostate Cancer Committee, Symposium Committee
  • 2004-present
    ASCO, Oncology Taskforce
  • 2005-present
    ASCO, Cancer Communications Committee, Roster of Cancer Experts
  • 2005-present
    American College of Radiology’s Appropriateness Criteria Expert Panel on Radiation Oncology-Prostate, AUA representative
  • 2006-present
    The Journal of Urology, Associate Editor
  • 2011 – present
    AUA Update, Editor
  • Honors:
  • 2001
    Ken and Donna Derr - Chevron Endowed Chair in Prostate Cancer
  • 2002
    Clinical Society of the American Association of Genitourinary Surgeons
  • 2004
    Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer
  • 2010
    AUA Eugene Fuller Triennial Prostate Award
  • 2010
    Society of Urologic Oncology Medal
  • 2014
    Barringer Medal, American Association of Genitourinary Surgeons

Selected Publications

  1. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021 Sep 16.  View on PubMed
  2. Kirk PS, Zhu K, Zheng Y, Newcomb LF, Schenk JM, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss M, Martin F, McKenney JK, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Gore JL. Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer. 2021 Sep 13.  View on PubMed
  3. Lonergan PE, Jeong CW, Washington SL, Herlemann A, Gomez SL, Carroll PR, Cooperberg MR. Active surveillance in intermediate-risk prostate cancer with PSA 10-20 ng/mL: pathological outcome analysis of a population-level database. Prostate Cancer Prostatic Dis. 2021 Sep 10.  View on PubMed
  4. Chang P, Wagner AA, Regan MM, Smith JA, Saigal CS, Litwin MS, Hu JC, Cooperberg MR, Carroll PR, Klein EA, Kibel AS, Andriole GL, Han M, Partin AW, Wood DP, Crociani CM, Greenfield TK, Patil D, Hembroff LA, Davis K, Stork L, Spratt DE, Wei JT, Sanda MG. Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. J Urol. 2021 Aug 26; 101097JU0000000000002176.  View on PubMed
  5. Vertosick EA, Zappala S, Punnen S, Hugosson J, Boorjian SA, Haese A, Carroll P, Cooperberg M, Bjartell A, Lilja H, Vickers AJ. Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. Urology. 2021 Aug 24.  View on PubMed
  6. Lonergan PE, Cowan JE, Washington SL, Greenberg SA, Nguyen HG, Carroll PR. Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort. Prostate. 2021 Sep; 81(13):1009-1017.  View on PubMed
  7. de la Calle CM, Shee K, Chu CE, Cowan JE, Nguyen HG, Carroll PR. Association of Age With Risk of Adverse Pathological Findings in Men Undergoing Delayed Radical Prostatectomy Following Active Surveillance. Urology. 2021 Sep; 155:91-95.  View on PubMed
  8. Salavati A, Gencturk M, Koksel Y, Schik AN, Carroll PR, Feng FY, Rowe SP, Lawhn-Heath C, Hope TA, Froelich JW. A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria? Eur J Nucl Med Mol Imaging. 2021 Jun 06.  View on PubMed
  9. Tilki D, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Mohamad O, Cowan JE, Feng FY, Carroll PR, Trock BJ, Partin AW, D'Amico AV. Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol. 2021 Jul 10; 39(20):2284-2293.  View on PubMed
  10. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Kageyama R, Wells DK, Chan JM, Friedlander T, Aggarwal R, Paris PL, Feng F, Carroll PR, Witte JS. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. JCO Precis Oncol. 2021; 5.  View on PubMed
  11. Greenberg SA, Washington SL, Lonergan PE, Cowan JE, Baskin AS, Nguyen HG, Odisho AY, Simko JP, Carroll PR. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen. J Urol. 2021 09; 206(3):706-714.  View on PubMed
  12. Maggi M, Del Giudice F, Falagario UG, Cocci A, Russo GI, Di Mauro M, Sepe GS, Galasso F, Leonardi R, Iacona G, Carroll PR, Cooperberg MR, Porreca A, Ferro M, Lucarelli G, Terracciano D, Cormio L, Carrieri G, De Berardinis E, Sciarra A, Busetto GM. SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study. Cancers (Basel). 2021 Apr 23; 13(9).  View on PubMed
  13. Salciccia S, Capriotti AL, Laganà A, Fais S, Logozzi M, De Berardinis E, Busetto GM, Di Pierro GB, Ricciuti GP, Del Giudice F, Sciarra A, Carroll PR, Cooperberg MR, Sciarra B, Maggi M. Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. Int J Mol Sci. 2021 Apr 22; 22(9).  View on PubMed
  14. Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, Durack JC, Stambler N, Lin T, Jensen J, Wong V, Siegel BA, Morris MJ. Reply by Authors. J Urol. 2021 07; 206(1):61.  View on PubMed
  15. Langlais CS, Chan JM, Kenfield SA, Cowan JE, Graff RE, Broering JM, Carroll P, Van Blarigan EL. Post-diagnostic coffee and tea consumption and risk of prostate cancer progression by smoking history. Cancer Causes Control. 2021 Jun; 32(6):635-644.  View on PubMed
  16. Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, Carroll PR, Schaeffer E, Feng FY. Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. Eur Urol. 2021 06; 79(6):717-721.  View on PubMed
  17. Gaylis FD, Cooperberg MR, Chen RC, Malin J, Loeb S, Witte JS, Carroll PR, Cohen ES, Dato PE, Lin DW, Zheng Y, Seibert TM, Setzler C, Wilt W, Gomez SL, Chan JML, Catalona WJ. Defining Quality Metrics for Active Surveillance: The Michigan Urological Surgery Improvement Collaborative Experience. Letter. J Urol. 2021 07; 206(1):171-172.  View on PubMed
  18. Carroll PR, Maggi M. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Reply. J Urol. 2021 07; 206(1):174.  View on PubMed
  19. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Sci Rep. 2021 Mar 03; 11(1):5040.  View on PubMed
  20. Tan WP, Rastinehad AR, Klotz L, Carroll PR, Emberton M, Feller JF, George AK, Gill IS, Gupta RT, Katz AE, Lebastchi AH, Marks LS, Marra G, Pinto PA, Song DY, Sidana A, Ward JF, Sanchez-Salas R, Rosette J, Polascik TJ, Focal Therapy Consensus group. . Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. Urol Oncol. 2021 Mar 03.  View on PubMed

Go to UCSF Profiles, powered by CTSI